Regeneron starts Phase 3 trial of Covid antibody drug that might treat and prevent infection, company says

(CNN)An antibody cocktail is now beginning late-stage clinical trials to evaluate the drug’s ability to prevent and treat coronavirus infection.

The biotechnology company Regeneron announced the late-stage clinical trials of REGN-COV2, its investigational double antibody cocktail for the treatment and prevention of Covid-19, in a news release on Monday.

Read more